GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Completed

Conditions: Diphtheria
Tetanus
Acellular Pertussis

Interventions: Biological: Boostrix®
Biological: Td (Tetanus diphtheria) vaccine

First Posted Date: 2006-03-01

Last Posted Date: 2014-01-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10000

Registration Number: NCT00297856

Locations: 🇺🇸
GSK Investigational Site, Oakland, California, United States

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Phase 1

Completed

Conditions: Herpes Simplex

Interventions: Drug: Valaciclovir

First Posted Date: 2006-02-28

Last Posted Date: 2017-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00297206

Locations: 🇿🇦
GSK Investigational Site, George, South Africa

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2006-02-28

Last Posted Date: 2016-02-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 148

Registration Number: NCT00297258

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

Phase 2

Completed

Conditions: Obesity

First Posted Date: 2006-02-28

Last Posted Date: 2015-04-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 136

Registration Number: NCT00297180

Locations: 🇺🇸
GSK Investigational Site, Portland, Oregon, United States

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Phase 3

Terminated

Conditions: HIV Infection

First Posted Date: 2006-02-27

Last Posted Date: 2009-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 406

Registration Number: NCT00297076

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-02-27

Last Posted Date: 2022-11-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 350

Registration Number: NCT00297063

Locations: GSK Investigational Site

Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors

Phase 3

Completed

Conditions: Depressive Disorder

Interventions: Drug: Placebo
Drug: 323U66 (Bupropion Hydrochloride Sustained Release)

First Posted Date: 2006-02-27

Last Posted Date: 2019-12-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 325

Registration Number: NCT00296517

Locations: 🇯🇵
GSK Investigational Site, Tottori, Japan

Study Of Patients With Allergic Rhinitis And Asthma

Phase 4

Completed

Conditions: Asthma

First Posted Date: 2006-02-27

Last Posted Date: 2016-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 600

Registration Number: NCT00296530

Locations: 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: fluticasone propionate/salmeterol (FSC)
Drug: fluticasone propionate (FP)
Drug: placebo nasal
Drug: montelukast (MON)
Drug: placebo DISKUS
Drug: ADVAIR DISKUS
Drug: placebo capsule

First Posted Date: 2006-02-27

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 725

Registration Number: NCT00296491

Locations: 🇵🇱
GSK Investigational Site, Lodz, Poland

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3

Completed

Conditions: Infections, Papillomavirus
Papillomavirus Vaccines

Interventions: Biological: Cervarix
Biological: Placebo control

First Posted Date: 2006-02-20

Last Posted Date: 2020-01-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 5752

Registration Number: NCT00294047

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy